Clinical Policy: Elbasvir/Grazoprevir (Zepatier)
Reference Number: OH.PHAR.PPA.08
Effective Date: 01.19
Last Review Date: 12.18
Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Grazoprevir/elbasvir (Zepatier®) is a fixed-dose combination product containing elbasvir, a hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor.

FDA Approved Indication(s)
Zepatier is indicated for treatment of chronic HCV genotype 1 or 4 infection in adults. Zepatier is indicated for use with ribavirin in certain patient populations.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Zepatier is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Chronic Hepatitis C Infection (must meet all):
      1. Diagnosis of chronic HCV infection as evidenced by detectable serum HCV RNA levels by quantitative assay in the last 90 days;
      2. Confirmed HCV genotype is 1 or 4;
         *Chart note documentation and copies of lab results are required
      3. For genotype 1a, laboratory testing for the presence or absence of virus with NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93;
      4. Documentation of the treatment status of the patient (treatment-naive or treatment-experienced);
      5. If cirrhosis is present, confirmation of Child-Pugh A status;
      6. Prescribed by, or in consultation with, a gastroenterologist, hepatologist, infectious disease specialist or other hepatitis specialist. Consult must be within the past year with documentation of recommended regimen;
      7. Age ≥ 18 years;
      8. Member is contraindicated to treatment with Mavyret due to current treatment with efavirenz or atazanavir;
         *See Appendix F for additional details on acceptable contraindications
      9. Member does not have limited life expectancy (less than 12 months) due to non-liver-related comorbid conditions;
      10. Documentation in provider notes (must be submitted) showing that member has had no abuse of alcohol and drugs for the previous 6 months. MUST submit urine drug screen for members with history of abuse of drugs other than alcohol. Counseling
MUST be provided and documented regarding non-abuse of alcohol and drugs as well as education on how to prevent HCV transmission;

11. Documentation of Metavir Fibrosis score, documentation of the method used and date fibrosis score was obtained;

12. Prescriber has discussed the importance of adherence to office visits, lab testing, imaging, procedures and to taking requested regimen as prescribed. Prescriber attests that member will be adherent to treatment plan;

13. If prescribed regimen includes ribavirin, the following criteria must be met (must meet all):
   a. Member or member’s partner(s) is NOT pregnant and is NOT planning to become pregnant during treatment or within 6 months of stopping;
   b. Agreement that member and their partner(s) will use two forms of effective contraception during treatment and for at least 6 months after stopping;
   c. Verification that monthly pregnancy tests will be performed throughout treatment;
   d. Members with CrCl <50 ml/min (moderate or severe renal dysfunction, ESRD, HD) should have dosage reduced;
   e. At the time of request, member does NOT meet any of the following:
      1) History of severe or unstable cardiac disease
      2) Diagnosis of hemoglobinopathy (e.g., thalassemia major, sickle cell anemia)
      3) Hypersensitivity to ribavirin
      4) Baseline platelet count <70,000 cells/mm3
      5) ANC <1500 cells/mm3
      6) Hb <12 g/dl in women or <13 g/dl in men

14. Member’s current medication list does NOT include: carbamazepine, phenytoin, rifampin, St. John’s Wort, efavirenz, atazanavir, darunavir, lopinavir, saquinavir, tipranavir, cyclosporine, naftilin, ketoconazole, bosentan, tacrolimus, etravirine, elvitegravir/cobicistat/emtricitabine/tenofovir (disoproxil fumarate or alafenamide), modafinil, daily doses exceeding the following: atorvastatin 20 mg or rosuvastatin 10 mg;

15. Prescribed regimen is consistent with an FDA or AASLD-IDSA recommended regimen (see Section V Dosage and Administration for reference);

16. Dose does not exceed elbasvir/grazoprevir 50 mg/100 mg (1 tablet) per day.

Approval duration: up to a total of 16 weeks*
(*Approved duration should be consistent with a regimen in Section V Dosage and Administration)

B. Other diagnoses/indications
   1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

II. Continued Therapy
   A. Chronic Hepatitis C Infection (must meet all):
      1. Member meets one of the following (a or b):
         a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
b. Must meet both of the following (i and ii):
   i. Documentation supports that member is currently receiving Zepatier for chronic HCV infection and has recently completed at least 60 days of treatment with Zepatier;
   ii. Confirmed HCV genotype is 1 or 4;
2. Member is responding positively to therapy;
3. Dose does not exceed elbasvir/grazoprevir 50 mg/100 mg (1 tablet) per day.

Approval duration: up to a total of 16 weeks*
(*Approved duration should be consistent with a regimen in Section V Dosage and Administration)

B. Other diagnoses/indications:
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
Appendix A: Abbreviation/Acronym Key
AASLD: American Association for the Study of Liver Diseases
APRI: AST to platelet ratio
FDA: Food and Drug Administration
FIB-4: Fibrosis-4 index
HBV: hepatitis B virus
HCC: hepatocellular carcinoma
HCV: hepatitis C virus
HIV: human immunodeficiency virus
IDSA: Infectious Diseases Society of America
IQR: interquartile range
MRE: magnetic resonance elastography
NS3/4A, NS5A/B: nonstructural protein
PegIFN: pegylated interferon
RBV: ribavirin
RNA: ribonucleic acid

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mavyret™ (glecaprevir/pibrentasvir)</td>
<td>Treatment-naïve chronic HCV infection: <strong>Genotypes 1 or 4</strong> Without cirrhosis: Three tablets PO QD for 8 weeks With compensated cirrhosis: Three tablets PO QD for 12 weeks</td>
<td>Mavyret: glecaprevir 300 mg/pibrentasvir 120 mg (3 tablets) per day</td>
</tr>
</tbody>
</table>
CLINICAL POLICY
Elbasvir/Grazoprevir

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mavyret™ (glecaprevir/pibrentasvir)</td>
<td>Treatment-experienced with IFN/pegIFN + RBV +/− sofosbuvir chronic HCV infection: Genotypes 1, 3, or 4</td>
<td>Mavyret: glecaprevir 300 mg/pibrentasvir 120 mg (3 tablets) per day</td>
</tr>
<tr>
<td></td>
<td>Without cirrhosis: Three tablets PO QD for 8 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>With compensated cirrhosis: Three tablets PO QD for 12 weeks</td>
<td></td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications

- Zepatier is contraindicated in:
  - Patients with moderate or severe hepatic impairment (Child-Pugh B or C) due to the expected significantly increased grazoprevir plasma concentration and the increased risk of alanine aminotransferase (ALT) elevations
  - With inhibitors of organic anion transporting polypeptides 1B1/3 (OATP1B1/3) inhibitors that are known or expected to significantly increase grazoprevir plasma concentrations, strong CYP3A inducers, and efavirenz
- If Zepatier is administered with RBV, the contraindications to RBV also apply.

Appendix D: Approximate Scoring Equivalencies using METAVIR F3/F4 as Reference

<table>
<thead>
<tr>
<th>Fibrosis/ Cirrhosis</th>
<th>Serologic Tests*</th>
<th>Radiologic Tests†</th>
<th>Liver Biopsy‡</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FibroTest</td>
<td>FIBRO Spect II</td>
<td>APRI</td>
</tr>
<tr>
<td>Advanced fibrosis</td>
<td>≥0.59</td>
<td>≥42</td>
<td>&gt;1.5</td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>≥0.75</td>
<td>≥42</td>
<td>&gt;1.5</td>
</tr>
</tbody>
</table>

*Serologic tests:
- FibroTest (available through Quest as FibroTest or LabCorp as FibroSure)
- FIBROSpect II (available through Prometheus Laboratory)
- APRI (AST to platelet ratio index)
- FIB-4 (Fibrosis-4 index: includes age, AST level, platelet count)

†Radiologic tests:
- FibroScan (transient elastography)
- MRE (magnetic resonance elastography)

‡Liver biopsy (histologic scoring systems):
- METAVIR F3/F4 is equivalent to Knodell, Scheuer, and Batts-Ludwig F3/F4 and Ishak F4-5/F5-6
- METAVIR fibrosis stages: F0 = no fibrosis; F1 = portal fibrosis without septa; F2 = few septa; F3 = numerous septa without cirrhosis; F4 = cirrhosis

Appendix E: Direct-Acting Antivirals for Treatment of HCV Infection
**CLINICAL POLICY**

*Elbasvir/Grazoprevir*

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Drug Class</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NS5A Inhibitor</strong></td>
<td><strong>Nucleotide Analog NS5B Polymerase Inhibitor</strong></td>
</tr>
<tr>
<td>Daklinza</td>
<td>Daclatasvir</td>
</tr>
<tr>
<td>Epclusa*</td>
<td>Velpatasvir</td>
</tr>
<tr>
<td>Harvoni*</td>
<td>Ledipasvir</td>
</tr>
<tr>
<td>Mavyret*</td>
<td>Pibrentasvir</td>
</tr>
<tr>
<td>Olysio</td>
<td></td>
</tr>
<tr>
<td>Sovaldi</td>
<td></td>
</tr>
<tr>
<td>Technivie*</td>
<td>Ombitasvir</td>
</tr>
<tr>
<td>Viekira XR/PAK*</td>
<td>Ombitasvir</td>
</tr>
<tr>
<td>Vosevi*</td>
<td>Velpatasvir</td>
</tr>
<tr>
<td>Zepatier*</td>
<td>Elbasvir</td>
</tr>
</tbody>
</table>

*Combination drugs*

**Appendix F: General Information**

- **Hepatitis B Virus Reactivation (HBV)** is a Black Box Warning for all direct-acting antiviral drugs for the treatment of HCV. HBV reactivation has been reported when treating HCV for patients co-infected with HBV, leading to fulminant hepatitis, hepatic failure, and death, in some cases. Patients should be monitored for HBV reactivation and hepatitis flare during HCV treatment and post-treatment follow-up, with treatment of HBV infection as clinically indicated.

- For patients infected with HCV Genotype 1a: Testing for the presence of virus with NS5A resistance-associated polymorphisms is recommended. Clinical trial results show decreased efficacy of Zepatier in HCV genotype 1a with presence of NS5A polymorphisms. If baseline NS5A polymorphisms are present for genotype 1a, refer to Section VI on the longer recommended duration of therapy.

- According to the September 2017 AASLD/IDSA HCV guidance updates, Zepatier plus Sovaldi is a recommended treatment option for patients treatment-experienced with pegIFN/RBV with compensated cirrhosis and genotype 3.

- **Child-Pugh Score:**

<table>
<thead>
<tr>
<th></th>
<th>1 Point</th>
<th>2 Points</th>
<th>3 Points</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bilirubin</strong></td>
<td><em>Less than 2 mg/dL</em>&lt;br&gt;<em>Less than 34 umol/L</em></td>
<td>2-3 mg/dL&lt;br&gt;34-50 umol/L</td>
<td>Over 3 mg/dL&lt;br&gt;Over 50 umol/L</td>
</tr>
<tr>
<td><strong>Albumin</strong></td>
<td>Over 3.5 g/dL&lt;br&gt;Over 35 g/L</td>
<td>2.8-3.5 g/dL&lt;br&gt;28-35 g/L</td>
<td>Less than 2.8 g/dL&lt;br&gt;Less than 28 g/L</td>
</tr>
<tr>
<td><strong>INR</strong></td>
<td>Less than 1.7</td>
<td>1.7 - 2.2</td>
<td>Over 2.2</td>
</tr>
<tr>
<td><strong>Ascites</strong></td>
<td>None</td>
<td>Mild / medically controlled</td>
<td>Moderate-severe / poorly controlled</td>
</tr>
<tr>
<td><strong>Encephalopathy</strong></td>
<td>None</td>
<td>Mild / medically controlled&lt;br&gt;Grade I-II</td>
<td>Moderate-severe / poorly controlled&lt;br&gt;Grade III-IV</td>
</tr>
</tbody>
</table>
**Clinical Policy**

**Elbasvir/Grazoprevir**

Child-Pugh class is determined by the total number of points: A = 5-6 points; B = 7-9 points; C = 10-15 points.

- **Acceptable medical justification for inability to use Mavyret (preferred product):**
  - Severe hepatic disease (Child-Pugh C): use of Mavyret is not recommended due to higher exposures of glecaprevir and pibrentasvir.
  - Moderate hepatic disease (Child-Pugh B): although not an absolute contraindication, use of Mavyret is not recommended in patients with moderate hepatic disease (Child-Pugh B) due to lack of safety and efficacy data.
    - Following administration of Mavyret in HCV infected subjects with compensated cirrhosis (Child-Pugh A), exposure of glecaprevir was approximately 2-fold and pibrentasvir exposure was similar to non-cirrhotic HCV infected subjects.
    - At the clinical dose, compared to non-HCV infected subjects with normal hepatic function, glecaprevir AUC was 100% higher in Child-Pugh B subjects, and increased to 11-fold in Child-Pugh C subjects. Pibrentasvir AUC was 26% higher in Child-Pugh B subjects, and 114% higher in Child-Pugh C subjects.
  - Drug-drug interactions with one or more the following agents:
    - Atazanavir
    - Efavirenz

- **Unacceptable medical justification for inability to use Mavyret (preferred product):**
  - Black Box Warning (BBW): currently or previously infected with hepatitis B virus. This BBW is not unique to Mavyret, and it applies across the entire therapeutic class of direct-acting antivirals for treatment of HCV infection. Therefore it is not a valid clinical reason not to use Mavyret.
  - Concurrent anticoagulant therapy: Fluctuations in International Normalized Ratio (INR) have been observed in warfarin recipients who were also receiving treatment for HCV infections. This BBW is not unique to Mavyret, and it applies across the entire therapeutic class of direct-acting antivirals for treatment of HCV infection. Although caution is advised when using Mavyret while receiving concurrent anticoagulant therapy, specifically warfarin, this is not an absolute contraindication as long as patient is adequately monitored and educated during therapy.
  - Drug-drug interactions with one or more of the following agents:
    - Rifampin, carbamazepine, or St. John’s wort:
    - These drug-drug interactions are not unique to Mavyret, and they apply across the entire therapeutic class of direct-acting antivirals for treatment of HCV infection.

**V. Dosage and Administration**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 1a: Treatment-naïve or pegIFN/RBV-experienced with or without compensated cirrhosis without baseline NS5A polymorphisms at amino acid positions 28, 30, 31, or 93</td>
<td>One tablet PO QD for 12 weeks</td>
<td>One tablet (grazoprevir 100 mg/ elbasvir 50 mg) per day</td>
<td>1) FDA-approved labeling 2) AASLD-IDSA (updated September 2017)</td>
</tr>
<tr>
<td>Indication</td>
<td>Dosing Regimen</td>
<td>Maximum Dose</td>
<td>Reference</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>Genotype 1a: Treatment-naive or PegIFN/RBV experienced with or without compensated cirrhosis with baseline NS5A polymorphisms at amino acid positions 28, 30, 31, or 93</td>
<td>One tablet PO QD plus weight-based RBV for 16 weeks</td>
<td>One tablet (grazoprevir 100 mg/ elbasvir 50 mg) per day</td>
<td>1) FDA-approved labeling  2) AASLD-IDSA (updated September 2017)</td>
</tr>
<tr>
<td>Genotype 1b: Treatment-naive or PegIFN/RBV experienced with or without compensated cirrhosis</td>
<td>One tablet PO QD for 12 weeks</td>
<td>One tablet (grazoprevir 100 mg/ elbasvir 50 mg) per day</td>
<td>1) FDA-approved labeling  2) AASLD-IDSA (updated September 2017)</td>
</tr>
<tr>
<td>Genotype 1a or 1b: pegIFN/RBV/NS3 PI* - experienced with or without compensated cirrhosis without baseline NS5A polymorphisms at amino acid positions 28, 30, 31, or 93</td>
<td>One tablet PO QD plus weight-based RBV for 12 weeks</td>
<td>One tablet (grazoprevir 100 mg/ elbasvir 50 mg) per day</td>
<td>1) FDA-approved labeling  2) AASLD-IDSA (updated September 2017)</td>
</tr>
<tr>
<td>Genotype 1a or 1b: pegIFN/RBV/NS3 PI* - experienced with or without compensated cirrhosis with baseline NS5A polymorphisms at amino acid positions 28, 30, 31, or 93</td>
<td>One tablet PO QD plus weight-based RBV for 16 weeks</td>
<td>One tablet (grazoprevir 100 mg/ elbasvir 50 mg) per day</td>
<td>1) FDA-approved labeling  2) AASLD-IDSA (updated September 2017)</td>
</tr>
<tr>
<td>Genotype 3*: pegIFN/RBV-experienced with compensated cirrhosis</td>
<td>One tablet PO QD plus sofosbuvir 400 mg for 12 weeks</td>
<td>One tablet (grazoprevir 100 mg/ elbasvir 50 mg) per day</td>
<td>AASLD-IDSA (updated September 2017)</td>
</tr>
<tr>
<td>Genotype 4: Treatment-naive with or without compensated cirrhosis</td>
<td>One tablet PO QD for 12 weeks</td>
<td>One tablet (grazoprevir 100 mg/ elbasvir 50 mg) per day</td>
<td>1) FDA-approved labeling  2) AASLD-IDSA (updated September 2017)</td>
</tr>
</tbody>
</table>


# Clinical Policy

## Elbasvir/Grazoprevir

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 4: PegIFN/RBV-experienced with or without compensated cirrhosis with virologic relapse/failure</td>
<td>Virologic relapse after prior pegIFN/RBV therapy: One tablet PO QD for 12 weeks Virologic failure while on pegIFN/RBV therapy: One tablet PO QD plus weight-based RBV for 16 weeks</td>
<td>elbasvir 50 mg) per day</td>
<td>One tablet (grazoprevir 100 mg/ elbasvir 50 mg) per day</td>
</tr>
</tbody>
</table>

AASLD/IDSA treatment guidelines for chronic hepatitis C infection are updated at irregular intervals; refer to the most updated AASLD/IDSA guideline for most accurate treatment regimen.

* NS3 protease inhibitor = telaprevir, boceprevir, or simeprevir

+ Off-label, AASLD-IDSA guideline-supported dosing regimen

## VI. Product Availability

Tablet: grazoprevir 100 mg with elbasvir 50 mg

## VII. References


<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>New policy created.</td>
<td>12.18</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan
CLINICAL POLICY
Elbasvir/Grazoprevir

retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.